Risk factor
Limited trading liquidity
Profitability factor
Undervalued vs peers
About
Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITDA, reasonably price
Target Price
The average target price of ILM1.DE is 22 and suggests 34% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell